On Tuesday, Shares of Monsanto Company (NYSE:MON), lost -1.50% to $92.86.
Monsanto Company, declared it will hold a series of webcasts in conjunction with its biennial investor event planned for November 17-18 in St. Louis, Mo. During presentations at the event, company executives will discuss product performance, the company’s planned initiatives, long-term growth drivers and future expectations, and other matters related to the company’s business.
- A webcast starting at 1 p.m. C.T. on Tuesday, November 17 will offer presentations from Hugh Grant, chairman and chief executive officer; Kerry Preete, executive vice president, global strategy; Brett Begemann, president and chief operating officer; Mike Frank, vice president, global commercial; and Mike Stern, vice president, and president and chief operating officer, The Climate Corporation.
- A webcast starting at 9 a.m. C.T. on Wednesday, November 18 will feature presentations from Robb Fraley, Ph.D., executive vice president and chief technology officer; and Pierre Courduroux, senior vice president and chief financial officer.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces raw crop seeds, counting corn, soybean, cotton, and canola seeds under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds, such as tomato, pepper, melon, cucumber, squash, beans, broccoli, onions, lettuce, and others under the Seminis and De Ruiter brands.
Shares of McDonald’s Corporation (NYSE:MCD), inclined 0.32% to $113.29, during its last trading session.
During the Company’s investor meeting , McDonald’s Corporation President and Chief Executive Officer Steve Easterbrook and members of senior administration offered an update on the Company’s Turnaround Plan and made the following declarations:
- The Company reiterated that it anticipates positive fourth quarter comparable sales in all segments
- Sales, Operating Income and One-year Return on Incremental Invested Capital targets for 2016 that are more compriseent with the Company’s formerly stated long-term financial targets
- Global refranchising target raised to 4,000 restaurants through 2018 with a new long-term aim to become 95% franchised
- Net annual G&A savings target raised to $500 million - the vast majority of which will be realized by the end of 2017
- McDonald’s Board of Directors raised the fourth quarter 2015 dividend by 5%, bringing the new quarterly dividend to $0.89 per share
- Plans to optimize the Company’s capital structure and improvement the cash return to shareholders target to about $30 billion for the three-year period ending 2016. The vast majority of the incremental cash return of $10 billion will be funded by issuing additional debt
- Decision to not pursue a REIT spin-off transaction
“The cornerstone of our System is our powerful and enduring brand. While we are still in the early stages of turning around our business, we are gaining momentum by focusing on our customers and what matters most to them - hot and fresh food, fast and friendly service, and a contemporary restaurant experience at the value of McDonald’s,” said Steve Easterbrook, President and Chief Executive Officer. “My priorities for McDonald’s as a modern, progressive burger company are three-fold: driving operational growth, creating brand excitement and enhancing financial value. We are taking bold, urgent action to reset the business and prepare the Company for the next chapter of its history.”
McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages.
Finally, Shares of Bristol-Myers Squibb Co (NYSE:BMY), ended its last trade with 0.09% gain, and closed at $65.05.
Bristol-Myers Squibb Company and Pfizer, declared that 22 abstracts will be presented at the American Heart Association (AHA) Scientific Sessions 2015, to be held November 7-11 in Orlando, Florida. The new data, counting four oral presentations, contribute to the Bristol-Myers Squibb and Pfizer Alliance’s research in nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) in patients treated with Eliquis. Abstracts comprise new data analyses from the pivotal Phase 3 study, ARISTOTLE, as well as a number of real-world data analyses.
“The Alliance is looking forward to sharing new data from both clinical and real-world data analyses,” said Douglas Manion, M.D., head of specialty development, Bristol-Myers Squibb. “These data demonstrate the Alliance’s commitment to continue to evaluate Eliquis in different settings.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.